Acid Pump Antagonist for Gastrointestinal Motility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications for gastrointestinal motility disorders in the hungry condition take several days to take effect and do not improve motility cooperatively with physiological contractions, leading to unmet needs in alleviating symptoms such as abdominal distension and discomfort.
Innovation Solution
An acid pump antagonist, represented by compounds like (-)-1-(2-methoxyethyl)-N,N,2-trimethyl-8-phenyl-1,6,7,8-tetrahydrochromeno[7,8-d]imidazole-5-carboxamide, is administered to inhibit gastric acid secretion, thereby enhancing and normalizing gastrointestinal motility, addressing the relationship between gastric acid secretion and motility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional drugs are used to treat gastrointestinal motility disorders, then the treatment covers a broad range of conditions, but the onset of effect takes several days and does not improve motility cooperatively with physiological contractions
Solution Approach 1:
The patent applies parameter changes by switching from conventional slow-acting motility drugs to acid pump antagonists that work through a different physiological mechanism. The acid pump antagonist rapidly reduces gastric acid secretion, which immediately removes the inhibitory effect on gastrointestinal motility, enabling rapid onset of action that coordinates with natural physiological contractions rather than forcing artificial stimulation.
2Speed
If compounds forcibly stimulate gastrointestinal motility, then immediate effect is achieved, but the contraction is not cooperative with physiological gastrointestinal motility
Solution Approach 1:
The patent converts the harmful effect of excessive gastric acid secretion into a beneficial therapeutic mechanism. By blocking the acid pump, the drug transforms the pathological high-acid state into a normal-acid state, which naturally restores coordinated gastrointestinal motility. The acid reduction itself becomes the therapeutic action that enables physiological contraction patterns rather than forcing artificial stimulation.
3Object-affected harmful factors
If gastric acid secretion is increased in hungry condition, then duodenal ulcer symptoms occur, but gastrointestinal motility decreases causing abdominal distension and discomfort
Solution Approach 1:
The patent applies inversion by treating the root cause (excessive gastric acid secretion) rather than the symptom (decreased motility). Conventional approaches tried to stimulate motility directly, but this patent inverts the approach by reducing gastric acid, which paradoxically restores normal motility. The acid reduction removes the pathological inhibition on gastrointestinal movement, simultaneously protecting against duodenal ulcers and eliminating abdominal distension.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The acid pump antagonist effectively alleviates or prevents symptoms of abnormal gastrointestinal motility by enhancing gastrointestinal motility, providing immediate relief and normalizing contractions in the gastric antrum and duodenum, making it a novel treatment for gastrointestinal function adjustment and motility activation.
Implementation Method 1
a reversible inhibitory activity of a gastric proton pump activity
Data Source
Figure 1~3
Figure 4
AI summary
The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.